Charles River Laboratories Announces Second-Quarter 2013 Results from Continuing Operations

Before you go, we thought you'd like these...
Before you go close icon

Charles River Laboratories Announces Second-Quarter 2013 Results from Continuing Operations

- Second-Quarter GAAP Sales of $292.9 Million and Non-GAAP Sales of $294.4 Million -

- Second-Quarter GAAP Earnings per Share of $0.58 and Non-GAAP Earnings per Share of $0.73 -


- Reaffirms Sales and Non-GAAP EPS Guidance for 2013; Reduces 2013 GAAP EPS Guidance -

- Increases Stock Repurchase Authorization by an Additional $100 Million -

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYS: CRL) today reported its results for the second quarter of 2013. For the quarter, net sales from continuing operations were $292.9 million, an increase of 2.9% from $284.7 million in the second quarter of 2012. On a non-GAAP basis and excluding the impact of foreign currency translation, which reduced sales by 1.1%, second-quarter 2013 net sales increased 4.6%. On a segment basis, sales increased in both the Research Models and Services (RMS) and Preclinical Services (PCS) segments.

On a GAAP basis, net income from continuing operations for the second quarter of 2013 was $28.6 million, or $0.58 per diluted share, compared to $30.5 million, or $0.63 per diluted share, for the second quarter of 2012.

On a non-GAAP basis, net income from continuing operations was $35.7 million for the second quarter of 2013, a decline of 1.9% from $36.4 million for the same period in 2012. Second-quarter diluted earnings per share on a non-GAAP basis were $0.73, a decrease of 2.7% compared to $0.75 per share in the second quarter of 2012. Lower operating income was the primary driver of the decline.

James C. Foster, Chairman, President and Chief Executive Officer, said, "We were pleased with our second-quarter results. We implemented actions to position the Company as the partner of choice for early-stage drug discovery and development, initiated targeted sales efforts which have enabled us to gain market share, and expanded our portfolio through strategic acquisitions. The benefit of these actions is clear in our second quarter results, and will drive revenue and earnings per share growth in 2013 and beyond."

Mr. Foster continued, "Based on our second-quarter results, we are reaffirming our sales and non-GAAP earnings per share guidance for 2013. We remain intently focused on our efforts to drive sales growth across all client segments and improve operating efficiency in order to enhance shareholder value."

Second-Quarter Segment Results

Research Models and Services (RMS)

Net sales for the RMS segment were $179.0 million in the second quarter of 2013, an increase of 3.1% from $173.6 million in the second quarter of 2012. On a non-GAAP basis and excluding foreign exchange, which reduced reported sales by 1.5%, RMS sales increased by 5.5%. Higher sales were driven primarily by the acquisitions of Vital River and Accugenix, as well as growth in the legacy Endotoxin and Microbial Detection (EMD) business.

In the second quarter of 2013, the RMS segment's GAAP operating margin was 27.7% compared to 32.0% for the second quarter of 2012. On a non-GAAP basis, the operating margin decreased to 30.0% from 32.8% in the second quarter of 2012. The non-GAAP operating margin decline was primarily attributable to lower legacy sales volume for research models and also to receipt of an insurance settlement in the second quarter of 2012 related to the 2011 disaster in Japan.

Preclinical Services (PCS)

Second-quarter 2013 net sales from continuing operations for the PCS segment were $114.0 million, an increase of 2.6% from $111.1 million in the second quarter of 2012. Excluding foreign exchange, which reduced reported sales by 0.5%, PCS sales increased by 3.1%. PCS sales growth was driven by increased sales to both large biopharmaceutical and mid-tier clients, primarily as a result of market share gains.

In the second quarter of 2013, the PCS segment's GAAP operating margin was 9.6% compared to 9.7% in the second quarter of 2012. On a non-GAAP basis, the operating margin decreased to 12.2% from 13.1% in the second quarter of 2012. The non-GAAP operating margin decrease was primarily attributable to a less favorable study mix and competitive pricing pressure.

Stock Repurchase Update

During the second quarter of 2013, the Company repurchased approximately 389,000 shares of its common stock for $16.6 million. As of June 29, 2013, Charles River had $31.8 million remaining on its $750 million stock repurchase authorization.

On July 30, 2013, the Board of Directors increased the stock repurchase authorization, which was originally approved in July 2010 at $500 million and increased to $750 million on October 20, 2010, by an incremental $100 million, for an aggregate amount of $850 million.

Six-Month Results

For the first six months of 2013, net sales increased by 2.4% to $584.2 million from $570.7 million in the same period in 2012. Foreign currency translation reduced reported sales by 1.0%.

On a GAAP basis, net income from continuing operations for the first half of 2013 was $54.6 million, or $1.11 per diluted share, compared to $57.0 million, or $1.17 per diluted share, for the same period in 2012.

On a non-GAAP basis, net income from continuing operations for the first half of 2013 was $68.9 million, or $1.42 per diluted share, compared to $70.3 million, or $1.45 per diluted share, for the same period in 2012.

Research Models and Services (RMS)

For the first six months of 2013, RMS net sales were $361.5 million, an increase of 1.3% from $356.8 million in the same period in 2012. Foreign currency translation reduced reported sales by 1.5%. On a GAAP basis, the RMS segment operating margin was 29.0% in the first half of 2013, compared to 32.2% for the prior-year period. On a non-GAAP basis, the operating margin was 30.7% in the first half of 2013, compared to 33.1% for the same period in 2012.

Preclinical Services (PCS)

For the first six months of 2013, PCS net sales were $222.7 million, an increase of 4.1% from $213.9 million in the same period in 2012. Foreign currency translation reduced reported sales by 0.4%. On a GAAP basis, the PCS segment operating margin was 8.5% in the first half of 2013, compared to 7.0% for the prior-year period. On a non-GAAP basis, the operating margin was 11.4% in the first half of 2013, compared to 11.1% for the same period in 2012.

2013 Guidance

The Company reaffirms its forward-looking guidance based on continuing operations for 2013 sales and non-GAAP earnings per share. The Company has reduced its 2013 GAAP earnings per share guidance to reflect changes to other items that have been excluded from non-GAAP results.

     
2013 GUIDANCE (from continuing operations) REVISED PRIOR
Net sales growth, reported 3.0% - 5.0% 3.0% - 5.0%
Negative impact of foreign exchange Approx. 1% Approx. 1%
Net sales growth, constant currency 4.0% - 6.0% 4.0% - 6.0%
GAAP EPS estimate$2.40 - $2.50$2.45 - $2.55
Amortization of intangible assets related to acquisitions$0.23$0.23
Operating losses (1)$0.05$0.05
Other items (2)$0.05$0.01
Convertible debt accounting $0.11 $0.11
Non-GAAP EPS estimate $2.80 - $2.90 $2.80 - $2.90

(1) These costs relate primarily to the Company's PCS-Massachusetts facility.
(2) Other items include severance related to cost-savings actions, costs associated with the evaluation of acquisitions, a government contract billing adjustment and related expenses, and the write-off of deferred financing costs and fees related to debt refinancing.

Webcast

Charles River Laboratories has scheduled a live webcast on Thursday, August 1, at 9:00 a.m. ET to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations of non-GAAP financial measures to comparable GAAP financial measures on the website.

Non-GAAP Reconciliations/Discontinued Operations

The Company reports non-GAAP results in this press release, which exclude certain items that are outside of normal operations. A reconciliation of GAAP to non-GAAP results is provided in the schedules at the end of this press release. In addition, the Company reports results from continuing operations, which exclude results of the Phase I clinical business that was divested in 2011. The Phase I business is reported as a discontinued operation.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share, which exclude the amortization of intangible assets and other charges related to our acquisitions, expenses associated with evaluating acquisitions, charges and operating losses attributable to businesses we plan to close, consolidate or divest, severance costs associated with our cost-savings actions, costs and adjustments related to our ongoing investigation of inaccurate billing with respect to certain government contracts, and the additional interest recorded as a result of the adoption in 2009 of an accounting standard related to our convertible debt accounting which increased interest and depreciation expense. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. This press release also refers to our sales in both a GAAP and non-GAAP (constant currency) basis. There are limitations in using non-GAAP financial measures, as they are not prepared in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions (and in certain cases, the evaluation of such acquisitions, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities, such as business acquisitions, happen infrequently and the underlying costs associated with such activities do not recur on a regular basis. Presenting sales on a constant currency basis allows investors to measure our sales growth net of foreign currency exchange fluctuations more clearly. Non-GAAP results also allow investors to compare the Company's operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in this press release, and can also be found on the Company's website at ir.criver.com.

Caution Concerning Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding our projected future financial performance including sales, earnings per share, and the expected impact of foreign exchange rates; the future demand for drug discovery and development products and services, including our expectations for future revenue trends; the development and performance of our services and products, including the impact this can have on our clients' drug development models; market and industry conditions including the outsourcing of these services and spending trends by our customers; the potential outcome of and impact to our business and financial operations due to litigation and legal proceedings, including with respect to our ongoing investigation of inaccurate billing with respect to certain government contracts; and Charles River's future performance as delineated in our forward-looking guidance, and particularly our expectations with respect to sales and foreign exchange impact. Forward-looking statements are based on Charles River's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the ability to successfully integrate businesses we acquire; the ability to execute our cost-savings actions on an effective and timely basis (including divestitures and site closures); the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our customers; the ability to convert backlog to sales; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 27, 2013, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law.

About Charles River

Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(dollars in thousands, except for per share data)
    

Three Months Ended

Six Months Ended

June 29,
2013

June 30,
2012

June 29,
2013

June 30,
2012

 
Total net sales$292,933$284,723$584,171$570,704
Cost of products sold and services provided 190,363  181,138  377,390  362,907 
Gross margin102,570103,585206,781207,797
Selling, general and administrative54,91949,900112,118105,877
Amortization of intangibles 4,463  4,411  8,712  8,906 
Operating income43,18849,27485,95193,014
Interest income (expense)(7,308)(7,928)(15,491)(16,178)
Other income (expense) 967  (1,346) 2,035  (1,690)
Income from continuing operations before income taxes36,84740,00072,49575,146
Provision for income taxes 8,219  9,453  17,941  18,129 
Income from continuing operations, net of tax28,62830,54754,55457,017
(Loss) income from discontinued operations, net of tax (915) 42  (1,070) 119 
Net income27,71330,58953,48457,136
Net loss (income) from noncontrolling interests (429) (121) (622) (229)
Net income attributable to common shareowners$27,284 $30,468 $52,862 $56,907 
 
Earnings per common share
Basic:
Continuing operations$0.58$0.63$1.12$1.18
Discontinued operations$(0.02)$-$(0.02)$-
Net$0.57$0.63$1.10$1.18
Diluted:
Continuing operations$0.58$0.63$1.11$1.17
Discontinued operations$(0.02)$-$(0.02)$-
Net$0.56$0.63$1.09$1.17
 
Weighted average number of common shares outstanding
Basic48,280,37148,029,74447,969,68348,142,347
Diluted48,835,45348,412,80048,647,94248,581,891
 

 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(dollars in thousands)
  
 

June 29,
2013

December 29,
2012

Assets
Current assets
Cash and cash equivalents$113,521$109,685
Trade receivables, net224,030203,001
Inventories88,40588,470
Other current assets92,91583,601
Current assets of discontinued businesses 886 495
Total current assets519,757485,252
Property, plant and equipment, net696,495717,020
Goodwill, net227,524208,609
Other intangibles, net90,21084,922
Deferred tax asset30,18738,554
Other assets53,91548,659
Long-term assets of discontinued businesses 3,510 3,328
Total assets$1,621,598$1,586,344
 
Liabilities and Equity
Current liabilities
Current portion of long-term debt & capital leases$16,163$139,384
Accounts payable37,29531,218
Accrued compensation45,00646,951
Deferred revenue53,69556,422
Accrued liabilities48,85845,208
Other current liabilities22,55721,262
Current liabilities of discontinued businesses 2,280 1,802
Total current liabilities225,854342,247
Long-term debt & capital leases619,771527,136
Other long-term liabilities104,604104,966
Long-term liabilities of discontinued businesses 8,979 8,795
Total liabilities 959,208 983,144
Non-controlling interests14,4392,395
Total equity 647,951 600,805
Total liabilities and equity$1,621,598$1,586,344
 

 
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)
(dollars in thousands)
     

Three Months Ended

Six Months Ended

June 29,
2013

June 30,
2012

June 29,
2013

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners

Gift Finder Promo
More to Explore
Sun, Dec 11
Set Your Location
City, State, or Zip